North America Vascular Graft Market size exceeded USD 686.1 million in 2020 and is estimated to witness over 5.4% CAGR from 2021 to 2027.

Vascular grafts are medical devices used in vascular bypass procedures to direct the blood flow from one area to another by reconnecting the blood vessels. There are different vascular grafts based on the indication and raw materials used for the graft to suit the host tissue. Further, these devices are widely used in endovascular aneurysm repair and haemodialysis access, among others.

Get more details on this report - Request Free Sample PDF

Increasing need for haemodialysis will propel the demand for vascular grafts. Growing number of end-stage renal disorders couple with growing number of patient pool with chronic kidney disease will lead to increase in dialysis procedures across the region. Also, patients undergoing haemodialysis require well-functional arteriovenous graft for efficient haemodialysis procedure. For instance, according to the National Kidney Foundation report, approximately 785,883 Americans had kidney failure and needed dialysis or a kidney transplant to survive in 2018. Thus, growing burden of chronic kidney disease will lead to high number of haemodialysis procedure.

North America Market, By Application

Endovascular aneurysm repair segment accounted for more than USD 295.9 million in 2020. High adoption rate for minimally invasive surgical procedures will propel the demand for endovascular aneurysm repair. Also, endovascular aneurysm repair offers cost-effective treatment to patients suffering from abdominal aortic aneurysm compared to open repair. In additions, complications associated with open repair procedures will lead to higher adoption of endovascular aortic repair, supplementing the segment growth.

North America Market, By Raw Material

Polyester grafts segment will show significant growth to reach USD 646.4 million by 2027. Polyester graft has wide array of indications such as abdominal & thoracic aortic aneurysms, peripheral artery disorder, and haemodialysis access. Also, high demand is credited to its various benefits such as a long lifespan, high patency, porousness, and easy availability of the material. Furthermore, increasing cardiovascular disease along with neurovascular disorders will have high impact on polyester graft segment growth.

North America Market, By End-use

Hospital segment dominated more than 62% market share in 2020 due to the rising number of minimally invasive surgical procedures in hospital setting and favourable reimbursement scenario for vascular grafts in U.S. Moreover, increasing government regulations to implement high quality patient care across the region will attract large patient pool in hospitals to seek treatments. Furthermore, growing disease burden and rising healthcare investments across the North America region will fuel the segment demand.

North America Market, By Country

U.S. market for vascular grafts is predicted to expand at 5.4% CAGR during the forecast timeframe. Development of novel and innovative vascular grafts for treatment of aortic aneurysms and vascular bypass will drive the industry growth across the region. In addition, key market players are focusing on launch of innovative and advanced vascular grafts through intensive R&D activities. For instance, W.L. Gore and Associates announced launch of VBX stent graft for treatment of restenosis lesions in iliac arteries. This graft was developed using EPTFE stent graft technology and is available in multiple sizes to cater needs of patients.

Competitive Industry Landscape

Major players operating in the market are Becton Dickinson (C.R. Bard), B. Braun Melsungen, Cook Medical, Endologix, Getinge AB, LeMaitre Vascular, Medtronic, among others.

Companies undertake various strategies such as mergers, collaborations, acquisitions, and geographic expansions to strengthen their market share. For instance, in March 2021, Cook Medical received FDA Breakthrough Device Designation for Zenith Fenestrated Endovascular Graft. The product provides more effective treatment or diagnosis for life-threatening or irreversibly debilitating diseases or conditions. This strategy is expected to add value to its existing portfolio as well as generate revenue from its sales.